1
|
Ratajczak J, Kubica A, Michalski P, Pietrzykowski Ł, Białczyk A, Kosobucka-Ozdoba A, Bergmann K, Buczkowski K, Krintus M, Jankowski P, Kubica J. Determinants of Lipid Parameters in Patients without Diagnosed Cardiovascular Disease-Results of the Polish Arm of the EUROASPIRE V Survey. J Clin Med 2023; 12:2738. [PMID: 37048821 PMCID: PMC10095493 DOI: 10.3390/jcm12072738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2023] [Revised: 03/31/2023] [Accepted: 04/05/2023] [Indexed: 04/08/2023] Open
Abstract
To assess the determinants of lipid parameters in primary care patients without diagnosed cardiovascular disease (CVD), a cross-sectional study was conducted during 2018-2019 with a total of 200 patients. The following lipid parameters were measured: total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), small, dense LDL (sdLDL-C), and lipoprotein (a) (Lp(a)). Predictors of elevated and adequately controlled lipid parameters were assessed with logistic regression analysis. Older age was related to higher risk of TC ≥ 6.2 mmol/L [OR 1.03 (95% CI 1.0-1.05)], sdLDL-C ≥ 1.0 mmol/L [OR 1.05 (95% CI 1.0-1.1)], and decreased risk of Lp(a) ≥ 50 mg/dL [OR 0.97 (95% CI 0.94-0.99)]. Patients with diabetes mellitus (DM) had increased probability of TG ≥ 2.25 mmol/L [OR 3.77 (95% CI 1.34-10.6)] and Lp(a) ≥ 50 mg/dL [OR 2.97 (1.34-6.10)] as well as adequate control of TG and Lp(a). Higher material status was related to lower risk of TC ≥ 6.2 mmol/L [OR 0.19 (95% CI 0.04-0.82)] and LDL-C ≥ 3.6 mmol/L [OR 0.33 (95% CI 0.12-0.92)]. High BMI was related to increased [OR 1.14 (95% CI 1.02-1.29)], and female gender [OR 0.33 (95% CI 0.12-0.96)] and hypertension [OR 0.29 (95% CI 0.1-0.87)] to decreased risk of TG ≥ 2.25 mmol/L [OR 1.14 (95% CI 1.02-1.29)]. Taking lipid-lowering drugs (LLD) was associated with LDL-C < 2.6 mmol/L [OR 2.1 (95% CI 1.05-4.19)] and Lp(a) < 30 mg/dL [OR 0.48 (95% CI 0.25-0.93)]. Physical activity was related to LDL-C < 2.6 mmol/L [OR 2.02 (95% CI 1.02-3.98)]. Higher abdominal circumference was associated with decreased risk of TG < 1.7 mmol/L [OR 0.96 (95% CI 0.93-0.99)]. Elevated lipid parameters were related to age, gender, material status, BMI, history of DM, and hypertension. Adequate control was associated with age, education, physical activity, LLD, history of DM, and abdominal circumference.
Collapse
Affiliation(s)
- Jakub Ratajczak
- Department of Cardiac Rehabilitation and Health Promotion, Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland
- Department of Cardiology and Internal Medicine, Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland
| | - Aldona Kubica
- Department of Cardiac Rehabilitation and Health Promotion, Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland
| | - Piotr Michalski
- Department of Cardiac Rehabilitation and Health Promotion, Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland
| | - Łukasz Pietrzykowski
- Department of Cardiac Rehabilitation and Health Promotion, Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland
| | - Aleksandra Białczyk
- Students’ Scientific Circle of Cardiology, Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland
| | - Agata Kosobucka-Ozdoba
- Department of Cardiac Rehabilitation and Health Promotion, Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland
| | - Katarzyna Bergmann
- Department of Laboratory Medicine, Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland
| | - Krzysztof Buczkowski
- Department of Family Medicine, Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland
| | - Magdalena Krintus
- Department of Laboratory Medicine, Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland
| | - Piotr Jankowski
- Department of Internal Medicine and Geriatric Cardiology, Center of Postgraduate Medical Education, 01-813 Warsaw, Poland
- Department of Epidemiology and Health Promotion, School of Public Health, Center of Postgraduate Medical Education, 01-826 Warsaw, Poland
| | - Jacek Kubica
- Department of Cardiology and Internal Medicine, Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland
| |
Collapse
|
2
|
Bustanji Y, Barham N, Abu-Rish EY, Alhyari A, Albustanji B, Alnajjar M, Abu-Irmaileh B, El-Huneidi W, Abu-Gharbieh E, Mohammad M, Fararjeh M, Issa A, Semreen M, Bajes H. Clinical investigation of lipoprotein (a) levels in type 2 diabetics for cariovascular diseases prediction and prognosis. Horm Mol Biol Clin Investig 2022; 43:263-271. [PMID: 35427448 DOI: 10.1515/hmbci-2021-0090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Accepted: 03/13/2022] [Indexed: 11/15/2022]
Abstract
OBJECTIVES We aimed to evaluate the levels of serum lipoprotein a, LP (a), in Jordanian patients with type 2 diabetes mellitus (DM); and to examine its relation to glycemic control, metabolic syndrome (MS) and duration of DM. The LP (a) is considered one of the independent risk factors for coronary artery disease (CAD) in the general population. METHODS Fasting blood samples were drawn from 51 diabetic patients with type 2 DM and 31 non-diabetic age and sex control subjects. Serum LP (a) was measured along with other parameters, including triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c) and glycosylated haemoglobin (HbA1c). Correlation analyses were performed between LP (a) and the various variables measured. RESULTS LP (a) measurement showed a skewed distribution towards the lower levels in both groups. Mean LP (a) levels showed a statistically insignificant difference between the two groups. No correlations of LP (a) were observed with age, sex or body mass index (BMI). No correlations of LP (a) with LDL-c, HDL-c, TG, TC, MS, DM duration or HbA1c were observed. The LP (a) serum levels were significantly higher in type 2 diabetic patients with retinopathy. CONCLUSIONS LP (a) serum levels are not increased in type 2 diabetic patients; so, LP (a) may not be a reliable marker for early therapeutic interventions in DM patients, even in high-risk for thrombosis groups.
Collapse
Affiliation(s)
- Yasser Bustanji
- Department of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, UAE.,School of Pharmacy, The University of Jordan, Amman, Jordan
| | - Noor Barham
- School of Pharmacy, The University of Jordan, Amman, Jordan
| | | | | | | | - Majd Alnajjar
- Hamdi Mango Center for Scientific Research, The University of Jordan, Amman, Jordan
| | - Bashaer Abu-Irmaileh
- Hamdi Mango Center for Scientific Research, The University of Jordan, Amman, Jordan
| | - Waseem El-Huneidi
- Department of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, UAE
| | - Eman Abu-Gharbieh
- Department of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, UAE
| | | | | | - Ala Issa
- School of Pharmacy, The University of Jordan, Amman, Jordan
| | | | - Hana Bajes
- School of Pharmacy, The University of Jordan, Amman, Jordan.,Science Department, Atlantic Cape Community College, Mays Landing, NJ 08330, USA
| |
Collapse
|
3
|
Peela JR, Latiwesh OB, Elshaari F, Hussain A, Tabrez E, Viglianco E, Edwards A, Ali F, Rawal AK. Investigating the Atherogenic Risk of Lipoprotein(a) in Type 2 Diabetic Patients. Cureus 2018; 10:e3030. [PMID: 30254819 PMCID: PMC6150746 DOI: 10.7759/cureus.3030] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Type 2 diabetes mellitus (T2DM) has high morbidity and results in increased risk of mortality mainly due to cardiovascular diseases. Different factors have been found to be responsible for the increased prevalence of coronary artery disease (CAD) in T2DM. One of these factors includes raised serum levels of lipoprotein(a) (Lp(a)). The present study was designed to evaluate the association of Lp(a) levels with T2DM in Libyan patients and find the degree of association between Lp(a), glycemic control, insulin, and lipid profile. The study included 100 T2DM patients, recruited from the Benghazi Center for Diagnosis and Treatment of Diabetes, and 30 apparently healthy age and sex-matched individuals, to serve as controls. All participants completed a questionnaire to obtain clinical information and medical history. Blood samples were collected and analyzed for Lp(a), fasting blood glucose (FBS), HbA1c, insulin, total cholesterol (TC), triglycerides (TAG), low-density lipoprotein c (LDL-c), and high-density lipoprotein c (HDL-c). The results from the comparison between the control and experimental groups showed that Lp(a) was significantly higher in diabetic patients. It showed the positive correlation with TC and LDL-c. On the contrary, it showed no significant correlations with glycemic control parameters nor insulin, TAG, HDL-c, body mass index (BMI), and blood pressor (BP). Cardiovascular disease (CVD) risk in type 2 diabetic patients could be dependent on risk factors other than LDL-c, which may not be an independent risk factor for the development and progression of atherogenesis in T2DM. Lp(a) may be a new metabolic syndrome risk factor, and it may be useful as a cardiovascular risk biomarker in future clinical practice.
Collapse
Affiliation(s)
| | - Omar B Latiwesh
- Medical Laboratory, Higher Institute of Medical Professions, Benghazi, LBY
| | - Farag Elshaari
- Biochemistry, Higher Institute of Medical Professions, Benghazi, LBY
| | - Azhar Hussain
- Medicine, Xavier University School of Medicine, Oranjestad, ABW
| | - Elsa Tabrez
- Medicine, St. Matthew's University School of Medicine, George Town, CYM
| | - Emily Viglianco
- Medicine, Xavier University School of Medicine, Oranjestad, ABW
| | - Ajené Edwards
- Medicine, Xavier University School of Medicine, Oranjestad, ABW
| | - Farwa Ali
- Medicine, American University of Antigua College of Medicine, New York, USA
| | - Avinash K Rawal
- Biochemistry, St. Matthew's University School of Medicine, Grand Cayman, CYM
| |
Collapse
|
4
|
Jeong HS, Kim JY, Lee SH, Hwang J, Shin JW, Song KS, Lee S, Kim J. Synergy of circulating miR-212 with markers for cardiovascular risks to enhance estimation of atherosclerosis presence. PLoS One 2017; 12:e0177809. [PMID: 28557988 PMCID: PMC5448743 DOI: 10.1371/journal.pone.0177809] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2016] [Accepted: 05/03/2017] [Indexed: 01/13/2023] Open
Abstract
Synergy of specific microRNAs (miRNAs) with cardiovascular risk factors to estimate atherosclerosis presence in ischemic stroke patients has not been investigated. The present study aimed to identify atherosclerosis-related circulating miRNAs and to evaluate interaction with other cardiovascular markers to improve the estimation of atherosclerosis presence. We performed a miRNA profiling study using serum of 15 patients with acute ischemic stroke who were classified by the presence of no (n = 8) or severe (n = 7) stenosis on intracranial and extracranial vessels, which identified miR-212, -372, -454, and -744 as miRNAs related with atherosclerosis presence. Of the 4 miRNAs, only miR-212 showed a significant increase in expression in atherosclerosis patients in a validation study (atherosclerotic patients, n = 32, non-atherosclerotic patients, n = 33). Hemoglobin A1c, a high-density lipoprotein cholesterol, and lipoprotein(a), both established risk markers, were independently related with atherosclerosis presence in the validation population. miR-212 enhanced the accuracy of atherosclerosis presence by the three existing markers (three markers, 78.5%; three markers+miR-212, 84.6%, P<0.05) and significantly added to the area under the receiver operating characteristic curve (three markers, 0.8258; three markers+miR-212, 0.8646, P<0.05). The inclusion of miR-212 increased the reclassification index calculated using net reclassification improvement (0.4527, P<0.05) and integrated discrimination improvement (0.0737, P<0.05). We identified circulating miR-212 as a novel marker of atherosclerosis. miR-212 enhanced the estimation of atherosclerosis presence in combination with hemoglobin A1c, high-density lipoprotein cholesterol, and lipoprotein(a). Thus, miR-212 is expected to improve the estimation of atherosclerosis using peripheral blood of patients.
Collapse
Affiliation(s)
- Hye Seon Jeong
- Neuroepigenetics Laboratory, School of Medicine and Hospital, Chungnam National University, Daejeon, South Korea
- Department of Neurology, School of Medicine and Hospital, Chungnam National University, Daejeon, South Korea
- Regional Cerebrovascular Center, Chungnam National University Hospital, Daejeon, South Korea
| | - Jee-Yeon Kim
- Neuroepigenetics Laboratory, School of Medicine and Hospital, Chungnam National University, Daejeon, South Korea
- Department of Neurology, School of Medicine and Hospital, Chungnam National University, Daejeon, South Korea
| | - Seo Hyun Lee
- Department of Information and Statistics, College of Natural Science, Chungnam National University, Daejeon, South Korea
| | - Junha Hwang
- Neuroepigenetics Laboratory, School of Medicine and Hospital, Chungnam National University, Daejeon, South Korea
- Department of Neurology, School of Medicine and Hospital, Chungnam National University, Daejeon, South Korea
| | - Jong Wook Shin
- Neuroepigenetics Laboratory, School of Medicine and Hospital, Chungnam National University, Daejeon, South Korea
- Department of Neurology, School of Medicine and Hospital, Chungnam National University, Daejeon, South Korea
- Regional Cerebrovascular Center, Chungnam National University Hospital, Daejeon, South Korea
| | - Kyu Sang Song
- Department of Pathology and Hunan Bio-Resource Bank, School of Medicine and Hospital, Chungnam National University, Daejeon, South Korea
| | - Sukhoon Lee
- Department of Information and Statistics, College of Natural Science, Chungnam National University, Daejeon, South Korea
| | - Jei Kim
- Neuroepigenetics Laboratory, School of Medicine and Hospital, Chungnam National University, Daejeon, South Korea
- Department of Neurology, School of Medicine and Hospital, Chungnam National University, Daejeon, South Korea
- Regional Cerebrovascular Center, Chungnam National University Hospital, Daejeon, South Korea
- * E-mail:
| |
Collapse
|
5
|
Quispe R, Manalac RJ, Faridi KF, Blaha MJ, Toth PP, Kulkarni KR, Nasir K, Virani SS, Banach M, Blumenthal RS, Martin SS, Jones SR. Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study. Atherosclerosis 2015; 242:243-50. [PMID: 26232164 DOI: 10.1016/j.atherosclerosis.2015.06.057] [Citation(s) in RCA: 96] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/18/2015] [Revised: 06/09/2015] [Accepted: 06/29/2015] [Indexed: 11/27/2022]
Abstract
BACKGROUND High levels of the triglycerides to high-density lipoprotein cholesterol (TG/HDL-C) ratio are associated with obesity, metabolic syndrome, and insulin resistance. OBJECTIVES We evaluated variability in the remaining lipid profile, especially remnant lipoprotein particle cholesterol (RLP-C) and its components (very low-density lipoprotein cholesterol subfraction 3 and intermediate-density lipoprotein cholesterol), with variability in the TG/HDL-C ratio in a very large study cohort representative of the general U.S. METHODS We examined data from 1,350,908 US individuals who were clinically referred for lipoprotein cholesterol ultracentrifugation (Atherotech, Birmingham, AL) from 2009 to 2011. Demographic information other than age and sex was not available. Changes to the remaining lipid profile across percentiles of the TG/HDL-C ratio were quantified, as well as by three TG/HDL-C cut-off points previously proposed in the literature: 2.5 (male) and 2 (female), 3.75 (male) and 3 (female), and 3.5 (male and female). RESULTS The mean age of our study population was 58.7 years, and 48% were men. The median TG/HDL-C ratio was 2.2. Across increasing TG/HDL-C ratios, we found steadily increasing levels of RLP-C, non-HDL-C and LDL density. Among the lipid parameters studied, RLP-C and LDL density had the highest relative increase when comparing individuals with elevated TG/HDL-C levels to those with lower TG/HDL-C levels using established cut-off points. Approximately 47% of TG/HDL-C ratio variance was attributable to RLP-C. CONCLUSIONS In the present analysis, a higher TG/HDL-C ratio was associated with an increasingly atherogenic lipid phenotype, characterized by higher RLP-C along with higher non-HDL-C and LDL density.
Collapse
Affiliation(s)
- Renato Quispe
- Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA.
| | - Raoul J Manalac
- Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA
| | - Kamil F Faridi
- Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA
| | - Michael J Blaha
- Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA
| | - Peter P Toth
- Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA; Department of Preventive Cardiology, CGH Medical Center, Sterling, IL, USA; University of Illinois College of Medicine, Peoria, IL, USA
| | | | - Khurram Nasir
- Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA; South Beach Preventive Cardiology Center, University of Miami, Miami, FL, USA
| | - Salim S Virani
- Michael E. DeBakey Veterans Affairs Medical Center and Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA
| | - Maciej Banach
- Department of Hypertension, Medical University of Lodz, Lodz, Poland
| | - Roger S Blumenthal
- Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA
| | - Seth S Martin
- Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA
| | - Steven R Jones
- Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA
| |
Collapse
|
6
|
Malaguarnera G, Gagliano C, Bucolo C, Vacante M, Salomone S, Malaguarnera M, Leonardi DG, Motta M, Drago F, Avitabile T. Lipoprotein(a) serum levels in diabetic patients with retinopathy. BIOMED RESEARCH INTERNATIONAL 2013; 2013:943505. [PMID: 23862162 PMCID: PMC3687764 DOI: 10.1155/2013/943505] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 04/30/2013] [Accepted: 05/21/2013] [Indexed: 12/15/2022]
Abstract
BACKGROUND Atherogenic lipoproteins, such as total cholesterol, LDL cholesterol, oxidized low density lipoprotein, and triglycerides, are associated with progression of retinopathy. Aim. To evaluate the relationship between lipoprotein(a) and retinopathy in patients with type 2 diabetes mellitus. MATERIALS AND METHODS We enrolled 145 diabetic consecutive patients (82 females, 63 males; mean age 66.8 ± 12 years, mean duration of diabetes 9.4 ± 6.8 years). Presence and severity of retinopathy were evaluated. Serum lipid profile, including Lp(a) level, was assessed. RESULTS High Lp(a) levels have been observed in 54 (78.3%) subjects and normal levels in 13 (18.85%) subjects as regards diabetic patients with retinopathy. Lp(a) levels were high in 15 subjects (21.75%) and normal in 63 subjects (91.35%) as regards patients without retinopathy. CONCLUSIONS Lp(a) levels are increased in a significant percentage of patients with retinopathy compared to diabetic patients without retinopathy. The impact of Lp(a) levels on diabetic retinopathy needs to be further investigated.
Collapse
Affiliation(s)
- Giulia Malaguarnera
- International Ph D Program in Neuropharmacology, University of Catania, 95123 Catania, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Qi Q, Qi L. Lipoprotein(a) and cardiovascular disease in diabetic patients. CLINICAL LIPIDOLOGY 2012; 7:397-407. [PMID: 23136583 PMCID: PMC3488449 DOI: 10.2217/clp.12.46] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Lipoprotein(a) (Lp[a]) is a LDL-like particle consisting of an ApoA moiety linked to one molecule of ApoB(100). Recent data from large-scale prospective studies and genetic association studies provide highly suggestive evidence for a potentially causal role of Lp(a) in affecting risk of cardiovascular disease (CVD) in general populations. Patients with Type 2 diabetes display clustered metabolic abnormalities and elevated risk of CVD. Lower plasma Lp(a) levels were observed in diabetic patients in several recent studies. Epidemiology studies of Lp(a) and CVD risk in diabetic patients generated inconsistent results. We recently found that Lp(a)-related genetic markers did not predict CVD in two diabetic cohorts. The current data suggest that Lp(a) may differentially affect cardiovascular risk in diabetic patients and in the general population. More prospective studies, Mendelian randomization analysis and functional studies are needed to clarify the causal relationship of Lp(a) and CVD in diabetic patients.
Collapse
Affiliation(s)
- Qibin Qi
- Department of Nutrition, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA
| | - Lu Qi
- Department of Nutrition, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA
- Channing Laboratory, Department of Medicine, Brigham & Women’s Hospital & Harvard Medical School, Boston, MA 02115, USA
| |
Collapse
|
8
|
Singla S, Kaur K, Kaur G, Kaur H, Kaur J, Jaswal S. Lipoprotein (a) in type 2 diabetes mellitus: Relation to LDL:HDL ratio and glycemic control. Int J Diabetes Dev Ctries 2009; 29:80-4. [PMID: 20142873 PMCID: PMC2812755 DOI: 10.4103/0973-3930.53125] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/07/2008] [Accepted: 05/29/2009] [Indexed: 11/08/2022] Open
Abstract
BACKGROUND Increased lipoprotein (a) [Lp (a)] concentrations are predictive of coronary artery disease (CAD). Type 2 diabetes mellitus also leads to dyslipidemia, like elevated triglyceride levels and low HDL levels, which are known risk factors for CAD. This study was designed to investigate the levels of Lp (a) in type 2 diabetic patients and their association with LDL: HDL ratio and glycemic control. MATERIALS AND METHODS The study included 60 patients of type 2 diabetes and 50 age and sex matched controls. The Lp(a) levels in the diabetic group were compared with the control group and the relationship between the Lp(a) levels and LDL: HDL ratio was evaluated. Diabetic group was further divided into three subgroups according to levels of glycated hemoglobin. Lp(a) levels and glycated hemoglobin in controlled and uncontrolled diabetes mellitus were also compared to find out any correlation between them. Statistical analysis was done using the students 't' test and Chi square test. RESULTS Lp(a) levels were found to be significantly increased in the diabetic group as compared to the control group (P< 0.001). LDL: HDL ratio was also increased in the diabetic group as compared to the control group. Lp(a) levels showed no association with LDL: HDL ratio and degree of glycemic control in these patients. CONCLUSIONS The results of the present study suggest that Lp(a) levels are increased in type 2 diabetic patients. The elevated Lp(a) levels do not reflect the glycemic status and are also independent of increase in LDL:HDL ratio suggesting different metabolic pathways and the genetic connection for LDL and Lp(a).
Collapse
Affiliation(s)
- Seema Singla
- Department of Biochemistry, Govt Medical College, Chandigarh, India
| | - Kiranjeet Kaur
- Department of Biochemistry, Govt Medical College, Patiala, India
| | - Gurdeep Kaur
- Department of Biochemistry, Govt Medical College, Patiala, India
| | - Habir Kaur
- Department of Medicine, Govt Medical College, Patiala, India
| | - Jasbinder Kaur
- Department of Biochemistry, Govt Medical College, Chandigarh, India
| | - Shivani Jaswal
- Department of Biochemistry, Govt Medical College, Chandigarh, India
| |
Collapse
|
9
|
Rahman S, Rahman T, Ismail AAS, Rashid ARA. Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes Metab 2007; 9:767-80. [PMID: 17924861 DOI: 10.1111/j.1463-1326.2006.00655.x] [Citation(s) in RCA: 151] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The complications associated with diabetic vasculopathy are commonly grouped into two categories: microvascular and macrovascular complications. In diabetes, macrovascular disease is the commonest cause of mortality and morbidity and is responsible for high incidence of vascular diseases such as stroke, myocardial infarction and peripheral vascular diseases. Macrovascular diseases are traditionally thought of as due to underlying obstructive atherosclerotic diseases affecting major arteries. Pathological changes of major blood vessels leading to functional and structural abnormalities in diabetic vessels include endothelial dysfunction, reduced vascular compliance and atherosclerosis. Besides, advanced glycation end product formation interacts with specific receptors that lead to overexpression of a range of cytokines. Haemodynamic pathways are activated in diabetes and are possibly amplified by concomitant systemic hypertension. Apart from these, hyperglycaemia, non-enzymatic glycosylation, lipid modulation, alteration of vasculature and growth factors activation contribute to development of diabetic vasculopathy. This review focuses on pathophysiology and pathogenesis of diabetes-associated macrovasculopathy.
Collapse
Affiliation(s)
- Sayeeda Rahman
- Department of Pharmacology, School of Medical Sciences, Kubang Kerian, University Sains Malaysia, Kelantan, Malaysia.
| | | | | | | |
Collapse
|
10
|
Siraj ES, Seyoum B, Saenz C, Abdulkadir J. Lipid and lipoprotein profiles in Ethiopian patients with diabetes mellitus. Metabolism 2006; 55:706-10. [PMID: 16713427 DOI: 10.1016/j.metabol.2005.08.002] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/23/2003] [Accepted: 08/08/2005] [Indexed: 11/18/2022]
Abstract
The association between dyslipidemia and diabetes mellitus is well established. Although various lipoprotein abnormalities have been described in patients with diabetes mellitus elsewhere, there is limited information from African patients. We undertook a cross-sectional study to assess the prevalence of dyslipidemia in Ethiopian patients with types 1 and 2 diabetes. A total of 193 subjects were included in the study (54 patients had type 1 diabetes mellitus, 92 patients had type 2 diabetes mellitus, and 47 were nondiabetic controls). Of these, 93 (48.6%) were men and 103 (51.4%) were women. The mean age+/-SEM for patients with type 1 diabetes mellitus, type 2 diabetes mellitus, and controls were 29.8+/-1.4, 51.2+/-1.1, and 29.0+/-1.7 years, respectively. Hypercholesterolemia and hypertriglyceridemia, defined as cholesterol level of greater than 5.2 mmol/L and triglyceride level of greater than 1.8 mmol/L, were found in 47.3% and 41.8% of patients with diabetes mellitus compared with 27% and 17% in controls (P<.05 for both). The mean total cholesterol level+/-SEM was significantly higher in patients with type 1 or 2 diabetes mellitus than controls (5.76+/-0.27 mmol/L in type 1 diabetes mellitus, 5.25+/-0.2 mmol/L in type 2 diabetes mellitus, and 4.67+/-0.28 mmol/L in healthy controls, P<.02). Triglycerides and low-density lipoprotein levels were also significantly higher in patients with diabetes than in controls, whereas high-density lipoprotein levels were significantly lower in patients with diabetes. In conclusion, our study demonstrates that in Ethiopians with diabetes mellitus, dyslipidemia occurs more frequently than in controls. Thus, we recommend periodic screening for dyslipidemia in all Ethiopian patients with diabetes. Other studies are needed to assess the potential negative effect of dyslipidemia and obesity on morbidity and mortality in Ethiopians with diabetes.
Collapse
Affiliation(s)
- Elias S Siraj
- Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic Foundation, Cleveland, OH, USA
| | | | | | | |
Collapse
|
11
|
Unlühizarci K, Muhtaroğlu S, Kabak S, Bayram F, Keleştimur F. Serum lipoprotein (a) levels in patients with diabetic foot lesions. Diabetes Res Clin Pract 2006; 71:119-23. [PMID: 16122830 DOI: 10.1016/j.diabres.2005.06.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/07/2003] [Revised: 04/22/2005] [Accepted: 06/02/2005] [Indexed: 11/15/2022]
Abstract
Our aim was to see the levels of lipoprotein (a) (Lp (a)) in patients with gangrenous or non-gangrenous diabetic foot lesions. Twenty-two patients with gangrenous foot lesions, 11 with non-gangrenous foot lesions and 10 healthy subjects were included in the study. All the patients had similar glycemic control and duration of diabetes. The main outcome measure was serum Lp (a) levels in both group of patients with diabetes and healthy subjects. Diabetic patients with gangrenous foot lesions had significantly higher Lp (a) levels (83.8+/-8.3 mg/dl) than the patients with non-gangrenous foot lesions (38.3+/-5.8 mg/dl) and healthy subjects (35.6+/-4.2 mg/dl). Lp (a) levels were not significantly different in healthy subjects and in patients with non-gangrenous foot lesions. Lp (a) levels may have a pathogenetic role in the development of gangrenous foot lesions in patients with diabetes mellitus.
Collapse
Affiliation(s)
- Kürşad Unlühizarci
- Department of Endocrinology, Erciyes University Medical School, Kayseri, Turkey
| | | | | | | | | |
Collapse
|
12
|
Abstract
The global prevalence of diabetes for all age groups is estimated to be 2.8%. Type 2 diabetes accounts for at least 90% of diabetes worldwide. Diabetes incidence, prevalence, and disease progression varies by ethnic group. This review highlights unique aspects of the risk of developing diabetes, its overwhelming vascular complications, and their management mainly using data among South Asians and African-Caribbeans in the UK but also using non-UK data. It is concluded that although the origin of the ethnic differences in incidence need further clarification, many factors should be amenable to prevention and treatment in all ethnic groups worldwide.
Collapse
Affiliation(s)
- J Oldroyd
- University Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK.
| | | | | | | |
Collapse
|
13
|
Ginier P, Deedwania P. Lipoprotein(a) in patients who have non-insulin-dependent diabetes with and without coronary artery disease. Endocr Pract 2005; 3:276-80. [PMID: 15251780 DOI: 10.4158/ep.3.5.276] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
OBJECTIVE To determine whether the level of lipoprotein(a) [Lp(a)] contributes to an increased risk of coronary artery disease (CAD) in patients with non-insulin-dependent diabetes mellitus (NIDDM). METHODS We prospectively evaluated established cardiovascular risk factors, metabolic control, and Lp(a) levels in 53 men with NIDDM and CAD and compared these variables in 42 male patients with NIDDM but without CAD. RESULTS The groups were comparable for age, diabetes control, treatment and duration of diabetes, obesity, and other cardiac risk factors. Lp(a) levels did not differ between the groups (12.2 versus 12.4 mg/dL in those with and without CAD, respectively) and were unrelated to age, duration of diabetes, diabetes control, obesity, smoking, hypertension, urinary albumin, cholesterol, triglycerides, or high-density lipoprotein cholesterol. Patients with retinopathy had a higher Lp(a) concentration than did those without retinopathy (24.9 +/- 6.0 versus 10.1 +/- 1.5 mg/dL; P = 0.01). A significant correlation existed between Lp(a) and low-density lipoprotein cholesterol concentrations (P = 0.01). CONCLUSION Routine measurement of Lp(a) level in patients with NIDDM does not seem warranted because no association was found between Lp(a) concentration and CAD in this study population.
Collapse
Affiliation(s)
- P Ginier
- University of California, San Francisco, California, USA
| | | |
Collapse
|
14
|
Moussa MAA, Alsaeid M, Abdella N, Refai TMK, Al-Sheikh N, Gomez JE. Lipoprotein(a) and Other Cardiovascular Metabolic Risk Factors in Kuwaiti Children with Type-1 Diabetes. ANNALS OF NUTRITION AND METABOLISM 2004; 48:329-34. [PMID: 15467283 DOI: 10.1159/000081200] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/29/2003] [Accepted: 04/20/2004] [Indexed: 11/19/2022]
Abstract
BACKGROUND/AIMS Lipoprotein(a) synthesis and catabolism could be influenced by insulin or by diabetes metabolic complications in patients with type-1 diabetes. The aim of the study was to investigate the relation of plasma lipoprotein(a) concentrations with metabolic cardiovascular risk factors in Kuwaiti children with uncomplicated type-1 diabetes. METHODS This case-control study included 115 (44 males and 71 females) diabetic children aged 6-18 years matched by age and sex to 115 non-diabetic children as controls. RESULTS There was no significant difference between the mean lipoprotein(a) concentrations in type-1 diabetic children (27.34 mg/dl) and their controls (22.80 mg/dl). Total cholesterol, apolipoprotein A1 and B levels were significantly higher in diabetic children than controls. In diabetic children, significant correlations were found between lipoprotein(a) levels and glycated hemoglobin (r = 0.249, p = 0.011), total cholesterol (r = 0.208, p = 0.025), and apolipoprotein B (r = 0.349, p < 0.001). The proportion of diabetic children with lipoprotein(a) >30 mg/dl was significantly higher in those having poor glycemic control (glycated hemoglobin >9.0%, p = 0.013), raised total cholesterol (p = 0.033), or with a family history of cardiovascular disease (p = 0.006). CONCLUSION Plasma lipoprotein(a) levels were not elevated in young type-1 diabetic children compared to non-diabetic controls; however, lipoprotein(a) levels were significantly higher in diabetic children with poor glycemic control. Moreover, there were significant correlations between lipoprotein(a) and the metabolic cardiovascular risk factors total cholesterol, atherogenic index, apolipoprotein B and apolipoprotein B/A1 ratio.
Collapse
Affiliation(s)
- M A A Moussa
- Department of Community Medicine and Behavioural Sciences, Faculty of Medicine, Kuwait University, Kuwait.
| | | | | | | | | | | |
Collapse
|
15
|
Abstract
AIM The aim of the present study was to analyze serum lipoprotein(a) [Lp(a)] levels in Pakistani patients with type 2 diabetes mellitus (DM) and to find correlations between clinical characteristics and dyslipidaemias in these patients. METHODS Fasting blood samples were analyzed for Lp(a), total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), glucose and glycosylated haemoglobin (HbA1c) in 68 Pakistani patients with type 2 DM and 40 non-diabetic healthy control subjects. RESULTS Lp(a) levels were significantly raised in diabetics as compared to the control group. No correlation of Lp(a) was seen with age, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP) and fasting glucose. There was a positive correlation of BMI to SBP and DBP. There was a significant positive correlation between Lp(a) and total cholesterol and LDL-c. No correlation of Lp(a) was observed with HDL-c, triglycerides and glycosylated haemoglobin (HbA1c). CONCLUSION The present study led us to conclude that serum Lp(a) levels are significantly raised in type 2 DM and have a positive correlation with serum total and LDL-c levels.
Collapse
Affiliation(s)
- S S Habib
- Department of Physiology, Army Medical College, Rawalpindi, Pakistan.
| | | |
Collapse
|
16
|
Psyrogiannis A, Habeos I, Kyriazopoulou V. Insulin sensitivity and Lp(alpha) concentrations in normoglycemic offspring of type 2 diabetic parents. Lipids Health Dis 2003; 2:8. [PMID: 14613579 PMCID: PMC272939 DOI: 10.1186/1476-511x-2-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2003] [Accepted: 10/29/2003] [Indexed: 12/01/2022] Open
Abstract
Background Offspring of at least 1 parent with type 2 diabetes are more resistant to the insulin action, exhibit higher incidence of dyslipidemia and are more prone to cardiovascular diseases. The association between Lp(α) and coronary heart disease is well established. An association between Lp(α) concentration and insulin sensitivity was examined in this study. We investigated the serum LP(α) in 41 offspring of 41 families of type 2 diabetic subjects (group I) with normal glucose tolerance, compared to 49 offspring who their parents had no history of type 2 diabetes, matched for sex, age, BMI, WHR and blood pressure (group II). Serum Lp(α), triglycerides, insulin resistant index, HDL, LDL-cholesterol and insulin were measured. Results The offspring of type 2 diabetic subjects had higher fasting serum triglycerides (mean ± SD 199.3 ± 184.2 vs. 147.1 ± 67.9 ng/dl, p < 0.05) lower HDL-cholesterol (37.3 ± 9.0 vs. 44.6 ± 7.8, p < 0.001) and particularly higher Insulin resistance Index (HOMA-IR) (2.84 ± 1.39 vs. 1.67 ± 0.77, p < 0.001). They also had higher serum LP(α) concentration (15.4 ± 6.7 vs. 8.6 ± 6.0, p < 0.001). By simple linear analysis in the offspring of type 2 diabetic parents there was no correlation of Lp(α) concentration with insulin resistance index Homa-IR (r = 0,016 p = NS). Conclusions We conclude that serum LP(α) is significantly increased in offspring of type 2 diabetic subjects but was not related to insulin sensitivity.
Collapse
Affiliation(s)
- Agathoklis Psyrogiannis
- Division of Endocrinology and Diabetes, Department of Medicine, University of Patras Medical School, Patras, Greece
| | - Ioannis Habeos
- Division of Endocrinology and Diabetes, Department of Medicine, University of Patras Medical School, Patras, Greece
| | - Venetsana Kyriazopoulou
- Division of Endocrinology and Diabetes, Department of Medicine, University of Patras Medical School, Patras, Greece
| |
Collapse
|
17
|
Tian H, Han L, Ren Y, Li X, Liang J. Lipoprotein(a) level and lipids in type 2 diabetic patients and their normoglycemic first-degree relatives in type 2 diabetic pedigrees. Diabetes Res Clin Pract 2003; 59:63-9. [PMID: 12482643 DOI: 10.1016/s0168-8227(02)00158-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
We investigated alterations of serum levels of Lp(a) and lipid profiles in type 2 diabetic patients and their normoglycemic first-degree relatives to evaluate the potential genetic association among these subjects. Serum Lp(a), triglycerride (TG), total cholesterol (TC), high density lipoprotein-cholesterol (HDL-C), and low density lipoprotein (LDL-C) levels were analyzed in 62 type 2 diabetic patients and 67 normoglycemic first-degree relatives from 29 type 2 diabetic pedigrees, and 45 healthy controls without family histories of diabetes. Dyslipidemia was observed in diabetics and their normoglycemic first-degree relatives. While higher serum TG levels were observed in both type 2 diabetics and their first-degree relatives than those in controls, higher TG levels in diabetics were found when compared with those in first-degree relatives. Meanwhile, lower serum HDL-C levels were observed in both type 2 diabetic patients and their first-degree relatives than those in controls. No significant difference of serum TC and LDL-C levels was found among the three groups. On the other hand, we did not observe significant differences of serum Lp(a) levels between type 2 diabetic patients and normoglycemic first-degree relatives, nor were any significant differences observed between diabetic patients and healthy controls (24.6+/-19.9 vs. 25.8+/-21.2, and 21.3+/-20.5 mg/dl). Although the average serum Lp(a) levels were similar in all subgroups, we did observe a positive correlation of Lp(a) between type 2 diabetic patients and their offspring (r=0.448, P<0.01), suggesting a potential genetic control for Lp(a) levels in type 2 diabetics families.
Collapse
Affiliation(s)
- Haoming Tian
- Department of Internal Medicine, West China Hospital, Sichuan University, 37 Guoxue Lane, Chengdu 610041, China.
| | | | | | | | | |
Collapse
|
18
|
Abstract
Diabetes mellitus is increasing throughout the world. Cardiovascular disease (CVD) accounts for up to 80% of excess mortality in this high-risk population. Patients with diabetes have the same CVD risk factors as those people without diabetes. However, these risk factors are much more powerful in diabetic patients. CVD risk is especially high for diabetic women, and premenopausal diabetic women lose all the protection normally afforded to them by female sex hormones. Controlled clinical trials have clearly demonstrated that rigorous treatment of blood pressure, dyslipidemia and platelet hyperaggrebility strikingly reduces CVD risk in diabetic patients. Strategies directed at interrupting the renin-angiotensin system (both tissue and systemic systems) and the use of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors have proven to be especially beneficial for this high-risk population.
Collapse
Affiliation(s)
- E Kassab
- Endocrinology, Diabetes and Hypertension, SUNY HSC at Brooklyn, NY 11203, USA
| | | | | |
Collapse
|
19
|
Alsaeid M, Qabazard M, Shaltout A, Sharma PN. Impact of glycemic control on serum lipoprotein (a) in Arab children with type 1 diabetes. Pediatr Int 2001; 43:246-50. [PMID: 11380917 DOI: 10.1046/j.1442-200x.2001.01387.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND Lipoprotein (a) (Lp (a)) is an independent risk factor for coronary artery disease (CAD), a major cause of death in patients with type 1 diabetes mellitus. Both type 1 diabetes and CAD represent major problems in Kuwait. Data on the effect of metabolic control on Lp (a) in diabetic children are limited and this is particularly true for Arab children. The objectives of the present study were to analyze serum Lp (a) levels in patients with type 1 diabetes compared with non-diabetic children, taking into account the effect of glycemic control. METHODS Circulating lipids, including Lp (a), were measured in serum samples from 60 prepubertal non-diabetic children and 58 prepubertal children with type 1 diabetes. Comparisons of Lp (a) concentrations were made between the non-diabetic and diabetic children with good to fair control (glycosylated hemoglobin (GHb) <11%) and a group of diabetic children with poor control (GHb > or = 11%). RESULTS The mean serum Lp (a) level in all diabetic children was 187.62+160.43 mg/L, compared with 162.88+156.06 mg/L in the control group. The group of children with poor glycemic control had higher median Lp (a) levels (147.50 mg/L) than either the group of diabetic children with good to fair control (95 mg/L; P<0.028) or the group of non-diabetic children (125 mg/L; P<0.04). Moreover, 38.3% of poorly controlled diabetic children had elevated Lp (a) levels > or = 250 mg/L, compared with 12.5% of diabetic children with good to fair control and 16.7% of non-diabetic children (P<0.025 and P<0.039, respectively). No association was found between Lp (a), diabetes duration and insulin dose. CONCLUSIONS In Arab children, highest Lp (a) levels are associated with poorest metabolic control. The prevalence of Lp (a) levels associated with cardiovascular risk is higher in poorly controlled diabetic children. Increased levels of Lp (a) may be another contributing factor to the high risk for CAD in diabetic patients.
Collapse
Affiliation(s)
- M Alsaeid
- Department of Pediatrics, Faculty of Medicine, Kuwait University, Kuwait.
| | | | | | | |
Collapse
|
20
|
Xiong Z, Wahlqvist ML, Biegler B, Balazs NDH, Buynder PV, Wattanapenpaiboon N. Plasma lipoprotein (a) concentrations and apolipoprotein (a) phenotypes in an Aboriginal population from Western Australia. Asia Pac J Clin Nutr 2000; 9:235-40. [DOI: 10.1046/j.1440-6047.2000.00190.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
21
|
Verrotti A, Lobefalo L, Chiarelli F, Mastropasqua L, Pallotta R, Colangelo L, Morgese G, Gallenga PE. Lipids and lipoproteins in diabetic adolescents and young adults with retinopathy. Eye (Lond) 1998; 11 ( Pt 6):876-81. [PMID: 9537151 DOI: 10.1038/eye.1997.225] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
PURPOSE To compare serum concentrations of lipoproteins and apolipoproteins in insulin-dependent diabetic patients with and without retinopathy. METHODS A cross-sectional study was performed on 42 diabetic adolescents and young adults with different degrees of retinopathy. The mean +/- SD age of the patient was 21.1 years (range 12.8-27.9 years); their mean duration of diabetes was 12.3 years (range 7.1-19.9 years). Their glycosylated haemoglobin (HbA1c) and fructosamine were respectively 10.2% (8.2-15.4%) and 280.8 mumol/l (202.1-458.5 mumol/l). Forty-two diabetics without retinopathy similar to the study population as regards age, sex, duration of disease, HbA1c and microalbuminuria values, and 42 healthy subjects, served as controls. RESULTS Serum lipid and lipoprotein concentrations were not different from those of healthy controls in patients either with or without retinopathy. The diabetic patients were subdivided in two groups according to the degree of their retinopathy: background and preproliferative/proliferative retinopathy. Patients with preproliferative/proliferative retinopathy were found to have significantly higher lipoprotein (a) values than the other group (background, 73.3 IU/l; preproliferative/proliferative, 205.9 IU/l; p < 0.001). CONCLUSION The increase in lipoprotein (a) levels might play a role in the development of severe retinopathy.
Collapse
Affiliation(s)
- A Verrotti
- Department of Paediatrics, University of Chieti, Italy
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Kayaba K, Nago N, Miyamoto T, Mizooka M, Terada M, Kario K, Nakamura Y, Igarashi M. Glycated hemoglobin levels and their correlation with atherosclerotic risk factors in a Japanese population--the Jichi Medical School Cohort Study 1993-1995. JAPANESE CIRCULATION JOURNAL 1998; 62:261-6. [PMID: 9583459 DOI: 10.1253/jcj.62.261] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We conducted a large population-based study to assess levels of glycated hemoglobin A1c (HbA1c) and to evaluate the correlation between HbA1c and other cardiovascular risk factors in Japan. A total of 910 men and 1,890 women aged 30-69 years participated in the Jichi Medical School Cohort Study (1993-95). Mean HbA1c was 5.61% in men and 5.49% in women. HbA1c levels were significantly correlated with levels of triglycerides, fibrinogen, and factor VII, and inversely correlated with high-density lipoprotein (HDL)-cholesterol level in both sexes. Lipoprotein(a) was inversely correlated in men. Blood pressure, body mass index (BMI), and total cholesterol were significantly associated with HbA1c in women. After adjusting for significant variables in univariate analyses, fibrinogen and factor VII remained as significant correlates in men, and BMI and total cholesterol in women. The authors conclude that HbA1c level is correlated not only with classical cardiovascular risk factors, but also with fibrinogen and factor VII. Our results suggest that HbA1c could be an alternative to blood glucose in evaluating atherosclerotic risk in a large-sized population study.
Collapse
Affiliation(s)
- K Kayaba
- Department of Community and Family Medicine, Jichi Medical School, Tochigi, Japan
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Ruiu G, Gambino R, Veglia F, Pagano G, Cassader M. Influence of APOH protein polymorphism on apoH levels in normal and diabetic subjects. Clin Genet 1997; 52:167-72. [PMID: 9377806 DOI: 10.1111/j.1399-0004.1997.tb02538.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Apolipoprotein (apo)H (also known as beta 2 glycoprotein-I) is a glycoprotein synthesized by liver cells and it is present in the blood associated with plasma lipoproteins. APOH displays a genetically determined structural polymorphism: three alleles (APOH*1, APOH*2, APOH*3) at a single locus on chromosome 17 code for different isoforms, and population studies have shown that APOH*2 is the most frequent allele. This paper assesses the relation between APOH phenotypes and plasma apoH levels in a population composed of 278 healthy subjects (243 H2/2, 32 H3/2, 2 H3/3, 1 H2/1; allele frequencies APOH*1 0.002, APOH*2 0.934, APOH*3 0.064) and 245 diabetics (212 H2/2, 30 H3/2, 3 H3/3; allele frequencies APOH*2 0.927 and APOH*3 0.073). Determination of apoH levels by competitive ELISA gave a mean value of 26.3 +/- 9.8 mg/dl for all subjects, 22.6 +/- 7.7 in normals vs 30.6 +/- 10.3 in diabetics (p = 0.0001), and 23.0 +/- 7.9, 19.3 +/- 5.4 and 18.5 +/- 3.5 mg/dl for H2/2, H3/2 and H3/3 in normals and 31.1 +/- 10.1, 28.2 +/- 10.8 and 15.7 +/- 9.0 mg/dl in diabetics, respectively. ANCOVA of the adjusted data revealed a significant difference in apoH levels for the three phenotypes in both the normal subjects (p = 0.01) and the diabetics (p = 0.02). ANCOVA of the whole samples of subjects, controlling for diabetes as well as age, sex and total cholesterol, indicated a substantial effect of phenotype, independent of the other variables (p = 0.0007).
Collapse
Affiliation(s)
- G Ruiu
- Department of Internal Medicine, University of Turin, Italy
| | | | | | | | | |
Collapse
|
24
|
Schneider DJ, Sobel BE. Determinants of coronary vascular disease in patients with type II diabetes mellitus and their therapeutic implications. Clin Cardiol 1997; 20:433-40. [PMID: 9134273 PMCID: PMC6655943 DOI: 10.1002/clc.4960200506] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/26/1996] [Accepted: 10/29/1996] [Indexed: 02/04/2023] Open
Abstract
Cardiovascular morbidity and mortality are increased 4- to 6-fold in patients with type II diabetes. The high prevalence is multifactorial and reflects in part the adverse influence of covariate, cardiac risk factors such as hypertension and hyperlipidemia. Type II diabetes is characterized by insulin resistance, hyperinsulinemia, and altered carbohydrate and lipid metabolism resulting in hyperglycemia, increased concentrations in blood of very low-density and low-density lipoproteins, and decreased blood high-density lipoproteins. Abnormalities seen predispose to vasculopathy through lipid deposition into vessel walls associated with monocyte infiltration, vascular smooth muscle cell proliferation, arterial mural fibrosis, and thrombosis. Conventional therapy for cardiovascular disease such as angioplasty and bypass surgery are of only limited efficacy. Thus, retardation of progression of atherosclerosis is essential. In addition to focusing on co-existent cardiac risk factors such as hypertension, therapy for patients with type II diabetes should reduce or reverse insulin resistance, improve metabolic control, and, ideally, do so without exacerbating hyperinsulinemia. Diet and exercise are central, and novel orally active hyperglycemic agents such as the biguanides and the thiazolidinediones that sensitize diverse tissues to insulin offer particular promise.
Collapse
Affiliation(s)
- D J Schneider
- Department of Medicine, University of Vermont, Burlington, USA
| | | |
Collapse
|
25
|
Chico A, Pérez A, Caixàs A, Ordóñez J, Pou JM, de Leiva A. Lipoprotein(a) concentrations and non-insulin-dependent diabetes mellitus: relationship to glycaemic control and diabetic complications. Diabetes Res Clin Pract 1996; 33:105-10. [PMID: 8879965 DOI: 10.1016/0168-8227(96)01285-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
UNLABELLED The aim of our study was to determine the lipoprotein(a) (Lp(a)) levels in patients with non-insulin-dependent diabetes mellitus (NIDDM) and to evaluate Lp(a) concentrations in relation to glycaemic control and diabetic complications. We evaluate in a cross-sectional study a total of 103 NIDDM patients (52 males and 51 females; mean age of 62.5 years; mean of diabetes duration: 12 years) referred to our hospital because of poor glycaemic control, and a group of 108 non-diabetic subjects (57 males and 51 females). RESULTS mean Lp(a) concentration did not significantly differ between NIDDM patients and non-diabetic subjects (11.1 +/- 14 vs. 16.2 +/- 14 mg/dl). The distribution of Lp(a) levels was highly skewed towards the lower levels in both groups, being over 30 mg/dl in only 6% of NIDDM patients and 12% of controls. Patients with Lp(a) levels over 10 mg/dl had lower haemoglobin Alc (HbA1c) than patients with Lp(a) levels over 10 mg/dl (8.5% vs. 10.4%; P < 0.01). Lp(a) concentration was positively correlated with body mass index (BMI) (P < 0.05) and HbA1c (P < 0.05). No association was found between Lp(a) and sex, age, other lipidic parameters, microalbuminuria, type of treatment and presence of cardiovascular disease. These findings may suggest that glycaemic control could have a modulatory role on Lp(a) concentration in NIDDM patients. In this study, diabetic complications did not seem to be associated with higher Lp(a) concentrations.
Collapse
Affiliation(s)
- A Chico
- Department of Endocrinology, hospital de la Santa Creu i Sant Pau, Autonomous University, Barcelona, Spain
| | | | | | | | | | | |
Collapse
|
26
|
Westerhuis LW, Venekamp WJ. Serum lipoprotein-a levels and glyco-metabolic control in insulin and non-insulin dependent diabetes mellitus. Clin Biochem 1996; 29:255-9. [PMID: 8740512 DOI: 10.1016/0009-9120(96)00002-5] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
OBJECTIVES Conflicting results for lipoprotein-a (Lp(a)) levels in diabetic patients exist in the literature. Normal, increased, and decreased values are described, and a relation to glycometabolic control is not unequivocally established. DESIGN AND METHODS In our study Lp(a) was measured in a large group of diabetiee (80 patients with IDDM and 90 patients with NIDDM) in relation to glycometabolic control and the presence of microalbuminuria, retino and/or neuropathy. Long-term and short-term glycometabolic control were assessed by HbA1 and fructosamine assays, respectively. RESULTS Statistically significant differences between Lp(a) levels in IDDM and NIDDM-and a control group of 110 healthy nondiabetics could not be established. It appeared that the level of Lp(a) in IDDM and NIDDM is independent of short-term and long-term glycometabolic control or the occurrence of microalbuminuria, neuro or retinopathy. However, poor glycometabolic control affected the number of Lp(a) levels elevated above a threshold of 0.25 g/L in IDDM. CONCLUSION These results suggest that the level of Lp(a) in serum is not influenced by diabetes mellitus, glycemic control, or the occurrence of microalbuminuria, neuro or retinopathy.
Collapse
Affiliation(s)
- L W Westerhuis
- Department of Clinical Chemistry, Ziekenhuis De Wever & Gregorius, Heerien The Netherlands
| | | |
Collapse
|
27
|
Abstract
Hypertension should be detected and treated early in diabetic patients. It has a marked contribution to the morbidity and mortality of diabetic individuals due to both atherosclerosis and microvascular disease. Antihypertensive treatment is an effective tool in slowing the progression of early and advanced diabetic nephropathy. Prospective studies addressing the effects of antihypertensive regimens on the incidence of CHF, stroke, and coronary artery disease in the diabetic population are not available. We assume that the beneficial effects of therapy apply to both diabetic and nondiabetic subjects. Glycemic control and the lipid profile are major concerns when selecting an antihypertensive drug. Because hyperinsulinemia and insulin resistance have been advocated as hypertensive and atherosclerotic risk factors, the effects of antihypertensive drugs on insulin action and plasma insulin levels may also become an important element in the selection of an antihypertensive agent. ACE inhibitors, calcium channel blockers, and alpha-adrenergic blockers probably offer the most favorable metabolic profile when compared with diuretics and beta-blockers and should be used as the initial drugs in most clinical settings.
Collapse
Affiliation(s)
- C Arauz-Pacheco
- Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, USA
| | | |
Collapse
|
28
|
Morishita E, Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, Yamazaki M, Aoshima K, Hashimoto T, Matsuda T. Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus. Atherosclerosis 1996; 120:7-14. [PMID: 8645373 DOI: 10.1016/0021-9150(95)05647-5] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Diabetes mellitus is associated with disturbances in hemostasis that could contribute to the development of diabetic vascular disease. We investigated the changes in parameters of blood coagulation and the fibrinolytic system and in plasma levels of lipoprotein(a)(Lp(a)) in 124 patients with type II diabetes mellitus and 44 healthy control subjects matched for age and body mass index (BMI) to determine whether hemostatic disturbances may lead to increased cardiovascular mortality. Median levels of fibrinogen (P < 0.0001), thrombin-antithrombin III complex (TAT) (P < 0.005), and plasminogen activator inhibitor-1 (PAI-1) activity (P < 0.05) in plasma were significantly elevated in diabetic patients compared with controls. The median concentration of Lp(a) was significantly higher in diabetic patients than in normal controls (18.2 vs. 12.6 mg/dl. P < 0.0005). Lp(a) levels tended to be elevated in patients with a prolonged history of diabetes. There was no evidence that Lp(a) levels were affected by metabolic control or by type of treatment. Twenty-two diabetics with coronary heart disease (CHD) had significantly higher levels of fibrinogen (P < 0.05), TAT (P < 0.05), and Lp(a) (24.7 vs. 13.7 mg/dl, P < 0.01) than the 51 patients without diabetic angiopathy. Our data indicate that impaired hemostatic balance in diabetes may cause hypercoagulability and may thus contribute to the increased cardiovascular mortality in diabetes.
Collapse
Affiliation(s)
- E Morishita
- Department of Laboratory Medicine, School of Medicine, Kanazawa University, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension 1995; 26:869-79. [PMID: 7490142 DOI: 10.1161/01.hyp.26.6.869] [Citation(s) in RCA: 297] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Because considerable important information has been published since our previous review, this update concentrates on new findings with regard to cardiovascular and renal risk factors contributing to the striking morbidity and mortality of these coexisting diseases. For example, a large body of investigative data has recently emerged suggesting or delineating a pathogenic role for hyperglycemic-related glycosylation and oxidation of lipoproteins and vascular and renal tissues. Great strides have recently been made in the understanding of platelet, coagulation, lipoprotein, and endothelial abnormalities in the pathogenesis of cardiovascular and renal disease associated with diabetes mellitus and hypertension. Major progress has been made in clarifying the pathophysiology of glomerulosclerosis and other processes involved in the progression of diabetic nephropathy. Furthermore, accumulating data surveyed in this review address new and promising pharmacological interventions that specifically address these pathophysiological mechanisms.
Collapse
MESH Headings
- Adrenergic alpha-Antagonists/therapeutic use
- Adrenergic beta-Antagonists/therapeutic use
- Adult
- Aged
- Angiotensin-Converting Enzyme Inhibitors/therapeutic use
- Arteriosclerosis/etiology
- Arteriosclerosis/metabolism
- Benzothiadiazines
- Calcium Channel Blockers/therapeutic use
- Cardiovascular Diseases/etiology
- Cells, Cultured
- Diabetes Complications
- Diabetes Mellitus/physiopathology
- Diabetes Mellitus/therapy
- Diabetes Mellitus, Type 1/complications
- Diabetes Mellitus, Type 1/therapy
- Diabetes Mellitus, Type 2/complications
- Diabetes Mellitus, Type 2/therapy
- Diabetic Nephropathies/metabolism
- Diabetic Nephropathies/physiopathology
- Diuretics
- Endothelium, Vascular/physiology
- Female
- Humans
- Hyperglycemia/complications
- Hypertension/complications
- Hypertension/physiopathology
- Hypertension/therapy
- Insulin/physiology
- Insulin-Like Growth Factor I/physiology
- Lipoproteins/blood
- Male
- Muscle, Smooth, Vascular/cytology
- Muscle, Smooth, Vascular/metabolism
- Platelet Adhesiveness
- Platelet Aggregation
- Sexual Dysfunction, Physiological/etiology
- Sodium Chloride Symporter Inhibitors/therapeutic use
Collapse
Affiliation(s)
- J R Sowers
- Wayne State University School of Medicine, Detroit, MI 48201, USA
| | | |
Collapse
|
30
|
|
31
|
Imperatore G, Rivellese A, Galasso R, Celentano E, Iovine C, Ferrara A, Riccardi G, Vaccaro O. Lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus and borderline hyperglycemia: a population-based study. Metabolism 1995; 44:1293-7. [PMID: 7476287 DOI: 10.1016/0026-0495(95)90032-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The objective of the study was to compare lipoprotein(a) [Lp(a)] concentrations in population-based samples of individuals with non-insulin-dependent diabetes mellitus (NIDDM), borderline hyperglycemia, and normoglycemia. From 2,740 male Italian Telephone Company employees aged 40 to 59 years participating in a health screening, we selected all those with NIDDM (n = 100) plus a random sample of 950 nondiabetic individuals. Diabetes was defined as fasting plasma glucose (FPG) of at least 140 mg/dL or current use of hypoglycemic drugs. Among nondiabetic individuals, 854 were defined as normoglycemic (FPG < 115 mg/dL) and 95 were defined as borderline hyperglycemic (115 < FPG < 140 mg/dL). Lp(a) level was measured on frozen plasma by enzyme-linked immunosorbent assay. Lp(a) concentrations were similar in people with NIDDM, borderline hyperglycemia, and normoglycemia: 11.2 +/- 14, 14.1 +/- 20, and 13.9 +/- 18 mg/dL, respectively (F = 1.03). Accordingly, the proportion of subjects with Lp(a) levels of at least 30 mg/dL was comparable in the three groups (12%, 15%, and 14%; chi 2 = 3.95, P = .41). Results were not confounded by differences in age, body mass index (BMI), waist to hip ratio, plasma lipids, alcohol consumption, physical activity, and use of drugs. Furthermore, within the diabetic group Lp(a) levels were not significantly different for those on diet only versus those on oral agents (10.8 +/- 14.1 v 11.7 +/- 14.7, P = .7) or for people with FPG of at least 180 as compared with people with FPG less than 180 mg/dL (9.9 +/- 12.8 v 11.5 +/- 14.8, P = .5).(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- G Imperatore
- Institute of Internal Medicine and Metabolic Diseases, Federico II University, Naples, Italy
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Abstract
Lipoprotein (a) is similar to low-density lipoprotein but is unique in having an additional apolipoprotein called apolipoprotein (a) (apo(a)) covalently linked to it. apo(a), which is a member of the plasminogen gene superfamily, has a protease domain which cannot be activated to cause fibrinolysis. Its sequence of kringles is much longer than that of plasminogen and there is remarkable genetic variation in its length. The consequent inherited differences in apo(a) molecular mass are largely responsible for the wide range of serum Lp(a) concentrations in different individuals with low levels predominating in Europid populations. Physiologically Lp(a) may participate in haemocoagulation or in wound-healing. Epidemiological evidence that it is a risk factor for atherosclerosis, particularly in populations with high serum LDL levels, has led to research to uncover its role in atherogenesis and thrombosis. Diseases such as renal disease, and probably atherogenesis and thrombosis. Diseases such as renal disease, and probably atherosclerosis itself, are associated with an increase in Lp(a) above its genetically determined level and it remains a subject of speculation as to whether such increases are as closely involved in atherothrombosis as are spontaneously high levels resulting from low-molecular-mass apo(a) variants.
Collapse
|
33
|
Purnell JQ, Marcovina SM, Hokanson JE, Kennedy H, Cleary PA, Steffes MW, Brunzell JD. Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial. Diabetes 1995; 44:1218-26. [PMID: 7556961 PMCID: PMC2866034 DOI: 10.2337/diab.44.10.1218] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Levels of lipoprotein(a) [Lp(a)], apolipoprotein (apo) B, and lipoprotein cholesterol distribution using density-gradient ultracentrifugation were measured as part of a cross-sectional study at the final follow-up examination (mean 6.2 years) in the Diabetes Control and Complications Trial. Compared with the subjects in the conventionally treated group (n = 680), those subjects receiving intensive diabetes therapy (n = 667) had a lower level of Lp(a) (Caucasian subjects only, median 10.7 vs 12.5 mg/dl, respectively; P = 0.03), lower apo B (mean 83 vs. 86 mg/dl, respectively; P = 0.01), and a more favorable distribution of cholesterol in the lipoprotein fractions as measured by density-gradient ultracentrifugation with less cholesterol in the very-low-density lipoprotein and the dense low-density lipoprotein fractions and greater cholesterol content of the more buoyant low-density lipoprotein. Compared with a nondiabetic Caucasian control group (n = 2,158), Lp(a) levels were not different in the intensive treatment group (median 9.6 vs. 10.7 mg/dl, respectively; NS) and higher in the conventional treatment group (9.6 vs. 12.5 mg/dl, respectively; P < 0.01). No effect of renal dysfunction as measured by increasing albuminuria or reduced creatinine clearance on Lp(a) levels could be demonstrated in the diabetic subjects. Prospective follow-up of these subjects will determine whether these favorable lipoprotein differences in the intensive treatment group persist and whether they influence the onset of atherosclerosis in insulin-dependent diabetes.
Collapse
Affiliation(s)
- J Q Purnell
- Division of Metabolism, Endocrinology, School of Public Health and Community Medicine, University of Washington, Seattle 98195, USA
| | | | | | | | | | | | | |
Collapse
|
34
|
Sowers JR, Epstein M. Diabetes Mellitus and Hypertension, Emerging Therapeutic Perspectives. ACTA ACUST UNITED AC 1995. [DOI: 10.1111/j.1527-3466.1995.tb00303.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
35
|
Abstract
Lipoprotein(a) has been identified as an independent risk factor for atherosclerotic vascular disease in non-diabetic populations. Because of its potential role in the pathogenesis of both microvascular and macrovascular complications in diabetes, there have recently been many reports on lipoprotein(a) in diabetic populations. Some studies indicate an association between elevated lipoprotein(a) and macrovascular disease in non-insulin-dependent diabetes mellitus (NIDDM), but this link has not been found with insulin-dependent diabetes mellitus (IDDM). In IDDM, elevated lipoprotein(a) has been found in groups with diabetic nephropathy and retinopathy, raising the possibility that it plays a causative role. The relationship between glycaemic control and the lipoprotein(a) level has not been fully resolved. Most studies have not found any connection in NIDDM, but some found higher lipoprotein(a) levels in hyperglycaemic IDDM patients. Potentially, lipoprotein(a) is an important factor linking the microvascular and macrovascular complications of diabetes.
Collapse
Affiliation(s)
- A J Jenkins
- Department of Medicine, University of Melbourne, St Vincent's Hospital, Victoria, Australia
| | | |
Collapse
|
36
|
Kuusi T, Yki-Järvinen H, Kauppinen-Mäkelin R, Jauhiainen M, Ehnholm C, Kauppila M, Seppälä P, Viikari J, Kujansuu E, Rajala S. Effect of insulin treatment on serum lipoprotein(a) in non-insulin-dependent diabetes. Eur J Clin Invest 1995; 25:194-200. [PMID: 7781667 DOI: 10.1111/j.1365-2362.1995.tb01548.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
In order to evaluate whether Lp(a), a lipoprotein that is potentially thrombogenic and atherogenic, is a potential risk factor for CAD in non-insulin-dependent diabetes (NIDDM), we compared the Lp(a) and its distribution in 145 NIDDM patients with that in 94 healthy control subjects. Furthermore, we studied the effect of insulin treatment on serum Lp(a) in 108 patients with NIDDM. Male and female NIDDM patients had similar Lp(a) concentrations to healthy controls (median value 167 mg L-1, range 15-1550 mg L-1 vs. 157 mg L-1, range 15-919 mg L-1, NS and 92, range 15-1190 mg L-1 vs. 103 mg L-1, range 15-842 mg L-1, NS). Also, the cumulative distribution of Lp(a) did not differ between the NIDDM patients and healthy subjects. Insulin treatment increased Lp(a) in diabetics with a Lp(a) concentration of less than 300 mg L-1, but this effect was not related to the concomitant improvement in metabolic control (mean change (+/- SEM) of HbA1c from 9.80 +/- 0.15 to 8.00 +/- 0.12; P < 0.001). In subjects with elevated Lp(a) concentrations (> 300 mg L-1) the Lp(a) concentration was unaffected by insulin, despite a similar improvement in glycaemic control. These results suggest that insulin may modulate the concentration of Lp(a).
Collapse
Affiliation(s)
- T Kuusi
- Third Department of Medicine, University of Helsinki, Finland
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Makino K, Furbee JW, Scanu AM, Fless GM. Effect of glycation on the properties of lipoprotein(a). Arterioscler Thromb Vasc Biol 1995; 15:385-91. [PMID: 7749849 DOI: 10.1161/01.atv.15.3.385] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Lipoprotein(a) [Lp(a)] was glycated by incubation in vitro with glucose (0 to 200 mmol/L), and its properties were compared with native Lp(a) and native and glycated LDL. Glucose was incorporated into Lp(a) in proportions that mirrored the distribution of lysines between apolipoprotein (apo) B-100 and apo(a). Because the kringle IV domains of apo(a) are lysine poor, only 10% of glucose bound to apo(a), whereas 90% was attached to the apoB-100 of Lp(a). Approximately 3% of the lysines of both Lp(a) and LDL were modified, which is a level comparable with that observed in LDL isolated from diabetic individuals. Glucose uptake by Lp(a) and LDL was almost identical and was linear as a function of concentration and time. Glycation increased the negative charge of Lp(a) and LDL as monitored by electrophoresis and ion-exchange chromatography and also reduced the affinity of Lp(a) and LDL for heparin-Sepharose. Glycation did not affect the lysine-binding property of Lp(a) or generate measurable malondialdehyde oxidation adducts. The catabolism of glycated Lp(a) by human monocyte-derived macrophages (HMDMs), like that of native Lp(a), was largely LDL receptor independent. Both glycated Lp(a) and LDL were degraded at a comparatively faster rate and stimulated greater cholesteryl ester formation than their unmodified counterparts. However, the degradation rate of glycated Lp(a) was approximately four- to fivefold slower and its stimulation of cholesteryl ester formation was ninefold lower than that of either form of LDL. These results show that Lp(a) can be glycated nonenzymatically in vitro, that the incorporation of glucose is dependent on the distribution of lysines between apo(a) and apoB-100, and that glycation does not affect the lysine-binding properties of Lp(a). Furthermore, glycation produced modest increases in the degradation rate of Lp(a) and associated cholesteryl ester synthesis by HMDMs. Based on these data, glycation does not appear to significantly enhanced the atherogenic potential of unmodified Lp(a).
Collapse
Affiliation(s)
- K Makino
- Department of Medicine, University of Chicago, IL 60637, USA
| | | | | | | |
Collapse
|
38
|
Tomkin GH, Owens D. Insulin and lipoprotein metabolism with special reference to the diabetic state. DIABETES/METABOLISM REVIEWS 1994; 10:225-52. [PMID: 7835171 DOI: 10.1002/dmr.5610100303] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
39
|
Abstract
Lipoprotein(a) [Lp(a)] is a plasma macromolecular complex that is assembled from low-density lipoproteins (LDL) and a large hydrophilic glycoprotein, named apolipoprotein(a) [apo(a)], linked by a disulfide bond to apolipoprotein B-100. Apo(a) is formed by different structural domains one of which is present in multiple copies, the number of which is determined by variation in the hypervariable apo(a) gene. Sequence homology of apo(a) with plasminogen may explain the competition of Lp(a) for some physiological functions of plasminogen in the coagulation and fibrinolytic cascade in vitro. There is evidence that high plasma levels of Lp(a) may have atherogenic and/or thrombogenic potential. More work will have to be done to understand the exact role of Lp(a) in atherogenesis, to evaluate the potential synergy between Lp(a) and LDL in promoting coronary artery disease, and to assess the therapeutic benefits of a reduction of Lp(a) levels.
Collapse
Affiliation(s)
- I Karmansky
- Department of Biochemistry, Lady Davis Carmel Hospital, Haifa, Israel
| | | |
Collapse
|
40
|
Abstract
In IDDM or NIDDM, the total plasma cholesterol and triglycerides are usually within normal limits when the blood glucose is controlled. Marked hypertriglyceridemia can develop with loss of glycemic control and is often due to superimposed genetic abnormalities in lipoprotein metabolism. Tight control in IDDM usually reduces LDL and VLDL to normal levels and may raise HDL above the normal range. Low HDL cholesterol and mild to moderate elevations of VLDL triglyceride are common in NIDDM if obesity or proteinuria is also present. Both HDL and LDL may be smaller and more dense and may be enriched with triglyceride as compared with cholesterol. These abnormalities may require weight loss for control. The increased incidence of cardiovascular disease in diabetes is unexplained but is amplified by the well-defined cardiovascular risk factors. The new American Diabetes Association guidelines call for treatment of high triglycerides and LDL cholesterol to be aggressively reduced. Triglycerides should be under 200 mg/dL, are considered borderline high between 200 and 400 mg/dL, and high when above 400 mg/dL. Low HDL is defined as less than 35 mg/dL. Control of obesity with diet and exercise and reduced intake of saturated fat and cholesterol are important first steps. If needed, drug therapy is appropriate to reduce LDL to levels below 130 mg/dL in all adult diabetics and below 100 mg/dL in those with cardiovascular disease.
Collapse
Affiliation(s)
- W V Brown
- Division of Arteriosclerosis and Lipid Metabolism, Emory University School of Medicine, Atlanta, Georgia
| |
Collapse
|
41
|
Haffner SM, Frangos M, Williamson J, Santiago J, Valdez R, Aldrete G, Mykkänen L, Gruber KK, Rainwater DL. Lp(a) concentrations and phenotypes in children with insulin-dependent diabetes mellitus. Chem Phys Lipids 1994; 67-68:223-31. [PMID: 8187217 DOI: 10.1016/0009-3084(94)90141-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Subjects with insulin-dependent diabetes mellitus (IDDM) have an increased incidence of coronary heart disease. Several studies have suggested that Lp(a) levels may be increased in IDDM subjects, although these studies have been limited by the lack of information on apo(a) phenotype and urinary albumin excretion. We compared Lp(a) concentrations in 66 children with IDDM and 18 non-diabetic children; all were non-Hispanic whites and none had detectable albuminuria. Lp(a) concentrations (mg/dl) were lower in subjects with IDDM than in non-diabetic subjects (12.0 +/- 2.2 vs. 20.0 +/- 6.1, respectively), although these means were not significantly different (P = 0.276). Postpubertal subjects, particularly males, had increased Lp(a) concentrations relative to prepubertal subjects (P = 0.041). Higher apo(a) molecular weight was associated with decreased Lp(a) concentrations in both diabetic and non-diabetic subjects. However, apo(a) size was not different in diabetic and non-diabetic subjects. Lp(a) concentrations were not significantly correlated with glycosylated hemoglobin levels in diabetic subjects (r = 0.11, P = NS). We also found similar Lp(a) concentrations in postpubertal IDDM subjects compared with adult non-Hispanic white non-diabetic subjects (n = 208) from the San Antonio Heart Study, a population-based study. These observations do not support increased Lp(a) concentrations in young normoalbuminuric IDDM subjects.
Collapse
Affiliation(s)
- S M Haffner
- Department of Medicine, University of Texas Health Science Center, San Antonio 78284-7873
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Elisaf M, Bairaktari H, Tzallas C, Germanos N, Koulouridis E, Pappas M, Siamopoulos KC, Tsolas O. Lipid parameters including Lp(a) in hemodialysis patients. Ren Fail 1994; 16:501-9. [PMID: 7938758 DOI: 10.3109/08860229409045081] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
Chronic hemodialysis (CHD) patients have a high incidence and prevalence of atherosclerotic disease which may be related to numerous atherosclerotic risk factors. Among them dyslipidemia plays a significant role. Elevated Lp(a) levels, which are strongly associated with atherosclerosis, have been reported recently in uremic patients. The aim of our study was the determination of the levels of lipid parameters including Lp(a) in 151 CHD patients (76 male) aged 57 (12-81) years, who were on hemodialysis for a mean of 44.3 (range 1 to 189) months. Eighty-four normal individuals age and sex matched were used as controls. The median serum Lp(a) concentration in hemodialysis patients was 13 mg/dL compared with 6.5 mg/dL in healthy controls, p < 0.001 by distribution-free Mann-Whitney test. The prevalence of subjects with Lp(a) levels above 25 mg/dL was significantly higher in CHD patients compared to normal subjects (30% vs. 8%, p < 0.001). Even if CHD patients were matched for fasting lipid levels, they showed Lp(a) levels significantly higher than controls. No significant correlation was found between Lp(a) levels and either the age of the patients or the duration of hemodialysis. The etiology of primary renal disease did not influence the Lp(a) levels.
Collapse
Affiliation(s)
- M Elisaf
- Department of Internal Medicine, University of Ioannina, Greece
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Reverter JL, Sentí M, Rubiés-Prat J, Lucas A, Salinas I, Pizarro E, Pedro-Botet J, Sanmartí A. Lipoprotein composition in the insulin-deficient non-acidotic phase of type I diabetic patients and early evolution after the start of insulin therapy. Clin Chim Acta 1993; 223:113-20. [PMID: 8143357 DOI: 10.1016/0009-8981(93)90067-e] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Lipoproteins, including intermediate density lipoproteins and lipoprotein(a), and apolipoproteins A-I, B, C-II, C-III and E, were studied in 13 newly-diagnosed type I diabetic patients with severe insulinopenia without dehydration or acidosis. At baseline, the main finding was a significant increase in serum triglycerides due to raised triglyceride concentrations in all lipoproteins, particularly triglyceride-rich lipoproteins. Cholesterol concentrations were slightly increased in lipoproteins and led to a significant increase in serum cholesterol. Two days after the start of insulin therapy, lipoprotein profiles had normalized except for the LDL triglyceride contents, which remained significantly increased on the fifth day of treatment. No significant modifications were observed in lipoprotein(a), apolipoproteins A-I and E concentrations throughout the study. However, serum apolipoproteins B, C-II and C-III were increased at baseline and fell to normal levels 2 days after the start of insulin therapy. On the other hand, apolipoprotein C-II/C-III ratios in high and very low density lipoprotein, showed no significant differences at baseline compared with controls, suggesting that an apolipoprotein C-II deficiency or apolipoproteins Cs imbalance can be ruled out. In conclusion, significant lipoprotein abnormalities were observed in the insulin-deficient state of type I diabetes mellitus; insulin therapy normalizes the lipoprotein profile in two days, except for low density lipoprotein triglyceride contents which remain increased at the fifth day.
Collapse
Affiliation(s)
- J L Reverter
- Endocrinology Section, Hospital Universitari, Germans Trias i Pujol, Badalona, Spain
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993; 36:1119-25. [PMID: 8270125 DOI: 10.1007/bf00401055] [Citation(s) in RCA: 178] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Numerous studies have shown that coagulation abnormalities occur in the course of diabetes mellitus, resulting in a state of thrombophilia. These observations are supported by epidemiological studies which demonstrate that thromboembolic events are more likely to occur in diabetic patients. The coagulation abnormalities observed in diabetic patients seem to be caused by the hyperglycaemia, which also constitutes the distinguishing feature of this disease. These data are also supported by in vitro studies which demonstrate how glucose can directly determine alterations in the coagulation system. The abnormalities observed involve all stages of coagulation, affecting both thrombus formation and its inhibition, fibrinolysis, platelet and endothelial function. The final result is an imbalance between thrombus formation and dissolution, favouring the former. Hyperglycaemia probably determines the onset of these abnormalities through three mechanisms which are, respectively, non-enzymatic glycation, the development of increased oxidative stress and a decrease in the levels of heparan sulphate. The first seems to affect the functionality of key molecules of coagulation in a negative sense. Oxidative stress constitutes an important pro-thrombotic stimulus, while the decrease in heparan sulphate determines a reduction in antithrombotic defenses. Good metabolic control could play a key role in controlling the coagulation irregularities in diabetes. However, considering the difficulties in achieving such an objective, it is possible that the use of drugs may represent a valid alternative. In fact, several drugs exist which are of potential interest. It is, however, necessary to perform long-term studies which demonstrate unequivocably that by controlling the coagulation abnormalities in diabetic patients, prolongation of life is possible.
Collapse
Affiliation(s)
- A Ceriello
- Department of Experimental and Clinica Pathology, University of Udine, Italy
| |
Collapse
|
45
|
Jerums G, Allen TJ, Tsalamandris C, Akdeniz A, Sinha A, Gilbert R, Cooper ME. Relationship of progressively increasing albuminuria to apoprotein(a) and blood pressure in type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetic patients. Diabetologia 1993; 36:1037-44. [PMID: 8243852 DOI: 10.1007/bf02374496] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
This study has explored the temporal relationship between apoprotein(a), blood pressure and albuminuria over a mean interval of 11 years in a cohort of 107 diabetic patients of whom 26 (14 Type 2 (non-insulin-dependent), 12 Type 1 (insulin-dependent) had progressively increasing albuminuria ('progressors'). In Type 2 diabetic patients, no significant differences were noted for HbA1, blood pressure, creatinine clearance or serum lipids between progressors and non-progressors. In Type 1 diabetic patients, final systolic and diastolic blood pressures were higher in progressors compared with non-progressors and progressors showed impairment of renal function in association with a rise in blood pressure at the macroalbuminuric stage. Initial apoprotein(a) levels were similar in progressors and non-progressors of either diabetes type. Apoprotein(a) levels increased exponentially with time in 12 of 14 Type 2 progressors but only in 5 of 12 Type 1 progressors (p < 0.01). In Type 2 diabetic patients, the annual increase in apoprotein(a) levels was 9.1 +/- 2.4%, which was significantly greater than in non-progressors, 2.0 +/- 1.2% (p < 0.01) and also exceeded the rates of increase of apoprotein(a) in progressors with Type 1 diabetes, 4.0 +/- 1.4%, (p < 0.05). Apoprotein(a) levels correlated significantly with albuminuria in 8 of 14 Type 2 progressors but only in 3 of 12 Type 1 progressors (p < 0.05). The rate of increase of apoprotein(a) levels was not related to mean HbA1, creatinine or creatinine clearance levels, or to albuminuria.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- G Jerums
- Department of Endocrinology, Austin Hospital, Heidelberg, Victoria, Australia
| | | | | | | | | | | | | |
Collapse
|
46
|
Heesen BJ, Wolffenbuttel BH, Leurs PB, Sels JP, Menheere PP, Jäckle-Beckers SE, Nieuwenhuijzen Kruseman AC. Lipoprotein(a) levels in relation to diabetic complications in patients with non-insulin-dependent diabetes. Eur J Clin Invest 1993; 23:580-4. [PMID: 8243530 DOI: 10.1111/j.1365-2362.1993.tb00969.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The relationship between serum levels of lipoprotein(a) Lp(a)) and the presence of chronic diabetic complications was studied in 194 patients with non-insulin-dependent diabetes mellitus (NIDDM; 75 males, 119 females; age 66 +/- 11 years; duration of diabetes, 11 (range 1-35) years). They were taking various treatments (diet alone, oral hypoglycaemic agents and/or insulin). Metabolic status and prevalence of diabetic complications were assessed by detailed history, physical examination, laboratory analysis and ECG. Average metabolic control was moderate (HbA1c 8.2 +/- 1.7%). Median serum Lp(a) level was 183 U l-1 (range 8-2600 U l-1), which was significantly higher than in control subjects of comparable age (median 101; range 8-1747 U l-1; P < 0.05), while HDL-cholesterol levels were lower (1.14 +/- 0.38 vs. 1.35 +/- 0.35 mmol l-1; P = 0.001), and total cholesterol levels were comparable. No significant relationships between diabetes treatment or metabolic control and Lp(a) levels were observed. In the quartile of patients with the highest Lp(a) levels, total cholesterol and triglycerides were slightly higher (P < 0.05), whereas HDL-cholesterol was not different. With increasing Lp(a) levels, higher prevalences of preproliferative retinopathy and of coronary artery disease (CAD) were observed, but not of the other complications. No relationship was found between the degree of albuminuria and Lp(a) levels. We conclude that in NIDDM patients, Lp(a) levels are elevated compared with non-diabetic subjects, and that higher Lp(a) levels are associated with higher prevalences of CAD and of retinopathy.
Collapse
Affiliation(s)
- B J Heesen
- Department of Internal Medicine, University Hospital, Maastricht, The Netherlands
| | | | | | | | | | | | | |
Collapse
|
47
|
Vendrell J, Gutiérrez C, Pastor R, Richart C. Plasma lipoprotein (a) concentration in diabetes mellitus. Diabetologia 1993; 36:881-2. [PMID: 8405763 DOI: 10.1007/bf00400367] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
|
48
|
Hegele RA, Connelly PW, Cullen-Dean G, Rose V. Elevated plasma lipoprotein(a) associated with abnormal stress thallium scans in children with familial hypercholesterolemia. Am J Cardiol 1993; 72:402-6. [PMID: 8352182 DOI: 10.1016/0002-9149(93)91130-a] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Plasma lipoprotein(a) (Lp(a)) concentrations are associated with an increased risk of coronary artery disease in adults with familial hypercholesterolemia (FH). We hypothesized that Lp(a) concentrations in children with FH were higher among those with myocardial ischemia on stress thallium scans and among those with a family history of premature coronary artery disease. Twenty-nine asymptomatic heterozygotes with FH (range 9 to 23 years) and 7 homozygotes (range 4 to 13 years) were evaluated with clinical assessment, lipoprotein measurement and stress thallium scans. Compared with subjects with normal stress thallium scans, mean Lp(a) was significantly higher in homozygotes with stress thallium abnormalities (79 +/- 18 vs 15 +/- 5.5 mg/dl, p = 0.03), and tended to be higher in heterozygotes with stress thallium abnormalities (39 +/- 12 vs 20 +/- 4.2 mg/dl, p = 0.10). Lp(a) tended to be higher in heterozygotes with a family history of premature coronary artery disease (30 +/- 6.4 vs 14 +/- 4.1 mg/dl, p = 0.12). It is concluded that Lp(a) is higher in hypercholesterolemic children who have abnormal stress thallium scans. Lp(a) may be useful in assessing coronary artery disease risk in children with FH.
Collapse
Affiliation(s)
- R A Hegele
- Department of Medicine, St. Michael's Hospital, Toronto, Ontario, Canada
| | | | | | | |
Collapse
|
49
|
Owens D, Cox M, Caird J, Gilligan S, Collins P, Johnson A, Tomkin GH. Altered regulation of cholesterol metabolism in type I diabetic women during the menstrual cycle. Diabet Med 1993; 10:647-53. [PMID: 8403827 DOI: 10.1111/j.1464-5491.1993.tb00139.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
This study examines the relationship of cellular cholesterol metabolism to oestrogen and progesterone during the menstrual cycle in diabetic and non-diabetic subjects. Nine premenopausal diabetic women were compared to nine non-diabetic women of the same age. Oestrogen, progesterone, lipoproteins, including lipoprotein (a) (Lp(a)) and cholesteryl ester transfer protein (CETP) were determined in serum. Cellular cholesterol content and cellular cholesterol synthesis were measured in mononuclear leucocytes. There was no significant change in serum lipoproteins including Lp(a) during the cycle in either group. CETP activity was significantly higher over the 4 weeks in the diabetic patients compared with non-diabetic subjects (mean 463 +/- 30 mumol l-1 h-1 vs 405 +/- 28 mumol l-1 h-1, p < 0.01). Serum high density lipoprotein (HDL) cholesterol was significantly lower during the 4 weeks in the diabetic patients (1.7 +/- 0.1 mmol l-1 vs 1.8 +/- 0.1 mmol-1, p < 0.05). Cellular cholesterol synthesis decreased steadily up to the third week in cells from the control subjects whereas there was no significant change in cells from diabetic patients whose cellular cholesterol synthesis was higher at week 3 compared with non-diabetic subjects (663 +/- 54 nmol mg-1 cell protein vs 432 +/- 43 nmol mg-1 cell protein, two-way interaction p < 0.05). There was a significant negative correlation between cellular cholesterol synthesis and serum oestrogen in the non-diabetic subjects (p < 0.05) but not in the diabetic patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- D Owens
- Department of Clinical Medicine, Trinity College, Dublin, Ireland
| | | | | | | | | | | | | |
Collapse
|
50
|
Affiliation(s)
- P E Pool
- North County Cardiology Research Laboratory, Encinitas, CA 92024
| |
Collapse
|